Original Article

Toxoplasma gondii destroys Her2/Neu-expressing mammary cancer cells in vitro using a continuous feed medium approach

Esra Atalay Şahar¹,², Mert Döşkaya¹, Muhammet Karakavuk³, Hüseyin Can⁴, Aytül Gül⁵, Adnan Yükseл Gürüz⁶, Aysu Değirmenci Döşkaya¹,⁶, Levent Yeniay⁷

¹ Department of Parasitology, Faculty of Medicine, Ege University, Bornova, İzmir, Turkey
² Department of Biotechnology, Graduate School of Natural and Applied Science, Ege University, Bornova, İzmir, Turkey
³ Ödemiş Vocational School, Ege University, Ödemiş, İzmir, Turkey
⁴ Molecular Biology Department, Faculty of Science, Ege University, Bornova, İzmir, Turkey
⁵ Department of Bioengineering, Faculty of Engineering, Ege University, Bornova, İzmir, Turkey
⁶ Blood Bank, Faculty of Medicine, Ege University, Bornova, İzmir, Turkey
⁷ Breast Cancer Unit, Department of General Surgery, Faculty of Medicine, Ege University, Bornova, İzmir, Turkey

Abstract

Introduction: Toxoplasma gondii is an opportunistic protozoan and can be grown using several human cell lines. Breast cancer is the second leading cause of cancer death in women. Her2/Neu-expressing mammary cancer cell lines called TUBO can be grown in vitro. In recent years, protozoan parasites have become popular means of use in cancer therapy research. In this study, we analyzed whether T. gondii tachyzoites can destroy TUBO cells using a novel continuous feed medium approach.

Methodology: Two sets of flasks (each containing four groups) containing TUBO cells were inoculated with T. gondii Ankara strain tachyzoites. First set containing 5x10⁶ TUBO cells were inoculated with TUBO-tachyzoite ratios of 1:2, 1:1, 2:1, and 4:1 and second set containing 1x10⁶ TUBO cells were inoculated with TUBO-tachyzoite ratios of 10:1, 100:1, 1000:1, and 2000:1. Thereafter, culture supernatants were harvested at various days until TUBO cells were destroyed and tachyzoites were counted.

Results: In the first and second sets of flasks, TUBO cells were destroyed between days 8 to 12 and 12 to 25, respectively. In addition, the amount of tachyzoites increased 7- 43 and 595 to 112500 times in the first and second set of flasks, respectively.

Conclusions: These results show that T. gondii tachyzoites successfully destroy Her2/Neu-expressing mammary cancer cells using a continuous feed medium approach. Although this idea may be too premature for the moment, the approach defined herein may support future researchers investigating the relationship between cancer and parasites which can make important progress toward saving cancer patient lives.

Key words: Toxoplasma gondii; cancer; breast cancer; in vitro; Her2/Neu; TUBO.

J Infect Dev Ctries 2020; 14(10):1204-1209. doi:10.3855/jidc.12820

(Received 15 April 2020 – Accepted 07 October 2020)

Copyright © 2020 Atalay Şahar et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Toxoplasma gondii is an opportunistic protozoan parasite that can infect all warm-blooded animals, birds, and humans [1-3]. T. gondii tachyzoites can be continuously grown in vitro using HFF (Human foreskin fibroblasts) cells for biological and structural studies [4].

In recent years, T. gondii has been analyzed for its anticancer properties [5-9]. T. gondii has shown to increase survival against lung ovarian cancer, melanoma, and pancreatic cancers in murine models [5, 6, 9]. These studies show the importance of T. gondii as a possible bioagent to fight against cancer. According to Zloza, 2018; researchers have begun to realize the limitlessness of the undiscovered area covering the interactions between pathogens and cancer [10]. Moreover, there are new knowledge and novel tools to uncover these interactions which can make important progress toward saving cancer patient lives [10].

T. gondii tachyzoites can invade and destroy various cell human cancer cell lines including HeLa (cervical cancer), Her-2 (human larynx carcinoma cells), and A549 (human lung carcinoma) [11-13]. T. gondii vaccine containing tachyzoites was found to effectively stimulate potent immunity, increasing survival, and preventing the recurrence of cancer types (6, 7, 9). Based on these data, we aimed to investigate whether T. gondii tachyzoites can invade and destroy...
breast cancer cells which has not been tested yet in *in vitro* or *in vivo* models.

The reason why we choose breast cancer cell line is that breast cancer is the most frequent diagnosed cancer in women worldwide [14]. Cancer occurs when the host immune system is not able to destroy or eliminate the abnormally dividing cells and fails to enclose the tumor [15]. HER2 (human epidermal growth factor receptor 2) or HER2/Neu is an oncogene that can be overexpressed in breast cancer and associated with recurrence and death [16]. The breast cancer cell line that we will use in this study is the Her2/Neu-expressing mammary cancer cell lines called TUBO [17]. Overall, we aimed to analyze whether *T. gondii* tachyzoites can invade and destroy Her2/Neu-expressing mammary cancer cells and determine the date TUBO cells were destroyed using a novel continuous feed medium approach.

**Methodology**

*T. gondii* Ankara strain tachyzoites and TUBO cell culture

*T. gondii* Ankara strain tachyzoites used in the present study belongs to Africa 1 genotype [18]. The *T. gondii* Ankara strain tachyzoites were cryopreserved and thawed to be used for this study with minor modifications as previously described [12,19]. Briefly, *T. gondii* Ankara strain tachyzoites continuously grown in HeLa cell line [12] were aspirated from the cell culture supernatant and centrifuged at 1500 rpm for 10 min. Then, the supernatant is discarded and the pellet is resuspended in 500 μL RPMI. The amount of *T. gondii* tachyzoites was counted with a haemocytometer and viability was determined using 0.4% trypan blue dye (AppliChem, Darmstadt, Germany). Thereafter, at least 10⁶ tachyzoites in 0.5 mL RPMI medium were added to 1 mL cryopreservation solution [15% (v/v) DMSO, 15% (v/v) fetal bovine serum (FBS) containing RPMI medium] and transferred to -80°C freezer. To thaw the cryopreserved tachyzoites, the tube containing cryopreserved material was immersed in to 37°C water bath until the solution dissolved. Next, the solution was immediately added to 5 mL of DMEM and centrifuged at 1500 rpm for 10 min. Thereafter, the supernatant was discarded and the pellet was resuspended in 500 μL DMEM. After thawing, the amount of tachyzoites was counted with a haemocytometer and viability was determined using 0.4% trypan blue dye (AppliChem, Darmstadt, Germany).

TUBO (a cell line cloned from a lobular carcinoma in BALB-neuT mice) cells kindly obtained from Prof. Federica Cavallo (University of Torino, Torino, Italy) were cultured in DMEM containing 20% fetal bovine serum (FBS) and penicillin (10U/mL) and streptomycin (10μg/mL) at 37°C in a 5% CO₂ atmosphere as previously described with some modifications [20]. As the monolayer formed in growth medium containing 20% FBS, 25-cm² flasks were washed once with 1×PBS, incubated with 0.25% trypsin for 5 min at 37°C and tapped sharply to release the cells from the bottom of the flask (Greiner, Frickenhausen, Germany). Subsequently 5 mL growth medium containing 20% FBS was added to the trypsinized cells and homogenized until a homogeneous cells suspension formed using a sterile Pasteur pipette. The viability of TUBO cells were counted with a haemocytometer and viability was determined with 0.4% trypan blue dye (AppliChem, Frickenhausen, Germany). Based on the amount of viable cells, an appropriate amount of TUBO cell was subcultured every 3-4 days into new 25-cm² flasks with growth medium containing 20%FBS and incubated at 37°C in a 5% CO₂ atmosphere to form the confluent monolayer. Unless noted otherwise, the entire cell culture media were obtained from Cegrogen, Germany (Stadtallendorf).

**Inoculation of TUBO cells with *T. gondii* Ankara strain tachyzoites**

As the monolayer formed and TUBO cells were released with trypsin and viability was determined with 0.4% trypan blue dye. Then, TUBO cells in 5 mL maintenance medium containing 2% FBS were added to 25-cm² flasks and incubated for an additional 16 hours. Next, two sets of 25-cm² flasks (each set contains four groups and each group contains three flasks) containing TUBO cells in maintenance medium were inoculated with *T. gondii* Ankara strain tachyzoites. The first set of four flasks containing 5×10⁶ TUBO cells were inoculated with TUBO-tachyzoite ratios of 2:1, 1:1, 1:2, and 1:4 at 37°C in a 5% CO₂ atmosphere. In the second set of four flasks, 1×10⁶ TUBO cells were inoculated with TUBO-tachyzoite ratios of 10:1, 100:1, 1000:1, and 2000:1 at 37°C in a 5 % CO₂ atmosphere.

In order to assess whether *T. gondii* Ankara strain tachyzoites can destroy TUBO cells, a feed medium approach was used. For this purpose, the cell supernatants were collected at days 3, 5, 7, 8, 10, 11, and 12 for the first set of flasks and at days 3, 5, 7, 11, 12, 13, 15, 18, 22, and 25 for the second set of flasks. The supernatant containing *T. gondii* Ankara strain tachyzoites were initially centrifuged at 250 rpm for 10 minutes and the pellet was discarded to remove host cell debris. The remaining supernatant containing *T. gondii* Ankara strain tachyzoites was centrifuged at 3000 rpm...
for 10 minutes. After centrifugation, the supernatant was discarded until 1 mL maintenance medium was left and then homogenized. Thereafter, the amount of TUBO cells and viable *T. gondii* Ankara strain tachyzoites were determined with a haemocytometer using 0.4 % trypan blue dye under phase-contrast inverted microscope (Nikon, Melville, USA). After counting, the homogenate was fed up to 5 mL with new maintenance medium.

For the flasks that the supernatant was aspirated, the remaining TUBO cells attached to each flask were washed with 1×PBS and then *T. gondii* Ankara strain tachyzoites in 5 mL feed maintenance medium were added to each corresponding flask. This approach was applied as we observed TUBO cells in each flask by microscopy after washing with 1×PBS. Negative control flasks that were not inoculated with *T. gondii* tachyzoites were also include to the study to assess the efficiency of feed maintenance medium approach in terms of TUBO cells attachment to the flasks. Experiments were performed in triplicate to obtain a mean ± SD for each set of experiments.

**Statistical analysis**

Data obtained during the study were processed using Microsoft Excel programme. The amount of tachyzoites obtained from three individual trials were calculated by microscopy and compared based on the average tachyzoite amount with standard deviation results.

**Results**

According to the results, we showed that *T. gondii* Ankara strain tachyzoites successfully invade TUBO cells *in vitro* as shown in Figure 1. In the first set of flasks, 5×10⁶ TUBO cells were inoculated with *T. gondii* tachyzoites at ratios of 1:2, 1:1, 2:1, and 4:1 using a continuous incubation with feed medium approach.

In the flasks that have TUBO-tachyzoite ratio of 1:2, the supernatant was aspirated and feeding of TUBO cells with new medium was performed at days 3 (Figure 2A), 5, and 7. TUBO cell culture was finalized at day 8 due to the absence of attached TUBO cells. The total amount of *T. gondii* tachyzoites was 69.5×10⁶ which was almost 7 times higher than the initial concentration (10×10⁶).

In the flasks that have TUBO-tachyzoite ratio of 1:1, TUBO cell culture was finalized at day 10 due to the absence of attached TUBO cells and the total amount of *T. gondii* tachyzoites were 66.25×10⁶ which was almost 11 times higher than the initial concentration (5×10⁶) (Figure 2A).

In the flasks that have TUBO-tachyzoite ratio of 2:1, TUBO cell culture was finalized at day 11 due to the absence of attached TUBO cells and the total amount of *T. gondii* tachyzoites were 55×10⁶ which was almost 22 times higher than the initial concentration (2.5×10⁶) (Figure 2A).

In the flasks that have TUBO-tachyzoite ratio of 4:1, TUBO cell culture was finalized at day 12 due to the absence of attached TUBO cells and the total amount of *T. gondii* tachyzoites were 54.25×10⁶ which was almost 43 times higher than the initial concentration (2.5×10⁶) (Figure 2A).

Accordingly, in the first set of flasks, as the amount of *T. gondii* Ankara strain tachyzoites that were inoculated to each flask decreased, the time that the TUBO cells were attached to each flask increased but at the same time the amount of viable tachyzoites increased compared to initial inoculate amount (Figure 2A and 2B).

In order to determine the survival time of TUBO cells using lower amount of *T. gondii* Ankara strain tachyzoites, a new set of flasks containing 1×10⁶ TUBO cells were inoculated with *T. gondii* Ankara strain tachyzoites at ratios of 10:1, 100:1, 1000:1, and 2000:1.

During continuous incubation with feed medium approach, in the flasks that have TUBO-tachyzoite ratio of 10:1, the supernatant was aspirated and feeding of TUBO cells with new medium was performed at days 3, 5, 7, and 11. TUBO cell culture was finalized at day 12 due to the absence of attached TUBO cells (Figure 2C). The total amount of *T. gondii* tachyzoites was almost 43 times higher than the initial concentration (2.5×10⁶) (Figure 2A).

**Figure 1.** Flask image of TUBO cells inoculated with *T. gondii* Ankara strain tachyzoites at a ratio of 1:1 at the third day of culture. Arrowhead showing a rosetta formation in TUBO cells typical for *T. gondii* invasion.
59.5×10^6 which was almost 595 times higher than the initial concentration (1×10^5).

In the flasks that have TUBO-tachyzoite ratio of 100:1, TUBO cell culture was finalized at day 13 due to the absence of attached TUBO cells and the total amount of *T. gondii* tachyzoites were 72.25×10^6 which was almost 7250 times higher than the initial concentration (1×10^6) (Figure 2C).

In the flasks that have TUBO-tachyzoite ratio of 1000:1, TUBO cell culture was finalized at day 22 due to the absence of attached TUBO cells and the total amount of *T. gondii* tachyzoites were 55×10^6 which was almost 55000 times higher than the initial concentration (1×10^4) (Figure 2C).

In the flasks that have TUBO-tachyzoite ratio of 2000:1, TUBO cell culture was finalized at day 25 due to the absence of attached TUBO cells and the total amount of *T. gondii* tachyzoites were 56.25×10^6 which was almost 112500 times higher than the initial concentration (5×10^2) (Figure 2C).

Accordingly, in the second set of flasks, as the amount of *T. gondii* Ankara strain tachyzoites that were initially inoculated to each flask decreased, the time that the TUBO cells were attached to each flask increased but at the same time the amount of viable tachyzoites increased compared to initial inoculate amount (Figure 2C and 2D). Although maintenance medium containing 2% FBS was used feed medium, TUBO cells also grew at a slower rate as shown in Figure 2 B and D. The amount of TUBO cells in cell culture supernatant were higher in second set of flasks possibly due to lower amount of *T. gondii* Ankara strain tachyzoite inoculation (Figure 2D). In the negative control flasks, TUBO cells were visualized in flasks forming a confluent layer up to 25 days using feed medium approach.

**Discussion**

*T. gondii* has been used in several studies to treat in vivo cancer models [5-9]. For example, a mutant strain called “Nonreplicating *Toxoplasma* uracil auxotrophs” has been found to effectively stimulate potent immunity and increased survival against ovarian cancer, melanoma, and pancreatic cancer bearing mice models [6,9]. In another study, *T. gondii* ME49 strain infection in mouse model inhibits tumor growth of Lewis lung carcinoma through the induction of Th1 immune responses and antiangiogenic activity [5]. *T. gondii*

---

**Figure 2.** The amount of viable *T. gondii* Ankara strain tachyzoites and TUBO cells obtained from cell culture supernatants collected at various days. The amount of (A) viable *T. gondii* Ankara strain tachyzoites and (B) TUBO cells counted in the first set of flasks using TUBO-tachyzoites ratios of 2:1, 1:1, 1:2, and 1:4. The amount of (C) viable *T. gondii* Ankara strain tachyzoites and (D) TUBO cells counted in the second set of flasks using TUBO-tachyzoites ratios of 10:1, 100:1, 1000:1, and 2000:1. (*) sign represents the days that the cell culture was finalized due to absence of TUBO cells in the flasks as observed by microscopy.
lysate antigen has also been used against tumor models in mice and showed suppression of angiogenesis as well as induction of IL-12 [21]. In addition to these in vivo studies, various in vitro studies showed that *T. gondii* tachyzoites can invade and destroy cervical cancer, larynx carcinoma and lung cancer cells [11-13].

In this study, we aimed to analyze whether *T. gondii* tachyzoites can destroy Her2/Neu-expressing mammary cancer cells in vitro using a novel continuous feed medium approach. During the continuous cell culture, the condition of TUBO cells was continuously observed and cell culture supernatants were collected at various days. *T. gondii* Ankara strain tachyzoites were collected from the supernatant and inoculated again in to corresponding flaks using fresh feed maintenance medium approach. Using this approach, we were able to extend culture of TUBO cells inoculated with *T. gondii* tachyzoites up to 25 days in the flasks in which TUBO-tachyzoite ratio was 2000:1.

According to the results, in the first and second sets of flasks, TUBO cells were finalized between days 8 to 12 and 12 to 25, respectively as detected by microscopy. In addition, the amount of *T. gondii* Ankara strain tachyzoites increased 7 to 43 times in the first set of flasks and 595 to 112500 times in the second set of flasks. The most important result of this study was, as low as 500 tachyzoites were able to destroy 1×10⁶ TUBO cells in 25 days. Altogether these results show that *T. gondii* Ankara strain tachyzoites successfully destroy Her2/Neu-expressing mammary cancer cells. Moreover, the continuous medium feed approach described in this study has not been tested before in any in vitro studies conducted by *T. gondii* tachyzoites.

In addition, our results as well as findings obtained from previous studies indicate that *T. gondii* tachyzoites have an affinity for cancerous cells. This relation between *T. gondii* and cancer cells have been showed by glycosylation studies. For example, cancer cells have excessive sialylation [22] and during penetration of *T. gondii* to these cancer cells, microneme protein 1 (TgMIC1) forms a complex with TgMIC4 and TgMIC6 and binds to sialylated glycolconjugates on cancer cell surface. It has also been reported that invasion efficiency of *T. gondii* tachyzoites reduces 90% when the host cells were treated by neuraminidase, an enzyme that cuts sialic acids present on cell surface [23].

**Conclusion**

The present study first time showed that *T. gondii* Ankara strain tachyzoites can successfully invade and destroy Her2/Neu-expressing mammary cancer cells in vitro using a continuous feed medium approach. It has also been showed that *T. gondii* tachyzoites have an affinity for cancerous cells, stimulate potent immunity and as a result increased survival against cancer in animal models. Although this idea may be too premature, future analyses investigating the relationship between *T. gondii* and cancer cells in terms of invasion and termination of cancer cells may shed important therapeutics tools in the future to save cancer patient lives. Overall, future studies aiming to use the termination power of *T. gondii* tachyzoites as showed in this study as well as immunostimulant efficacy of the parasite may have additive efficacy against cancer types.

**Acknowledgements**

The authors would like to acknowledge Prof. Federica Cavallo and Irene Fiore Merighi (University of Torino, Turin, Italy) for providing TUBO cells and technical assistance for the maintenance of TUBO cells in our lab. This study was partly supported by the grant given by the Scientific Research Projects Branch Directorate of Ege University, Turkey (Grant No: 2016TIP082) to L.Y.

**References**

1. Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363: 1965-1976.
2. Dubey JP (2009) Toxoplasmosis of Animals and Humans, 2nd edition. Boca Raton, FL: CRC Press 295 p.
3. Mohamed K (2020) Toxoplasmosis in humans and animals in Saudi Arabia: A systematic review. J Infect Dev Ctries 14: 800-811. doi: 10.3855/jidc.12648.
4. Khan A, Grigg ME (2017) *Toxoplasma gondii*: laboratory maintenance and growth. Curr Protoc Microbiol 44: 1-21.
5. Kim JO, Jung SS, Kim SY, Kim TY, Shin DW, Lee JH, Lee YH (2007) Inhibition of Lewis lung carcinoma growth by *Toxoplasma gondii* through induction of Th1 immune responses and inhibition of angiogenesis. J Korean Med Sci 22 (Suppl): 38-46.
6. Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR, Fiering S, Bzik DJ (2013) Avirulent *Toxoplasma gondii* generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res 73: 3842-3851.
7. Fox BA, Sanders KL, Chen S, Bzik DJ (2013) Targeting tumors with nonreplicating *Toxoplasma gondii* uracil auxotroph vaccines. Trends Parasitol 29: 431-437.
8. Fox BA, Sanders KL, Rommereim LM, Guevara RB, Bzik DJ (2016) Secretion of rhoptry and dense granule effector proteins by nonreplicating *Toxoplasma gondii* uracil auxotrophs controls the development of antitumor immunity. PLoS Genet 12: e1006189.
9. Fox BA, Butler KL, Guevara RB, Bzik DJ (2017) Cancer therapy in a microbial bottle: Uncorking the novel biology of the protozoan *Toxoplasma gondii*. PLoS Pathog 13: e1006523.
10. Zloza A (2018) Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer. J Immunother Cancer 6: 3.
11. Evans R, Chatterton JM, Ashburn D, Joss AW, Ho-Yen DO (1999) Cell-culture system for continuous production of Toxoplasma gondii tachyzoites. Eur J Clin Microbiol Infect Dis 18: 879-884.
12. Döskaya M, Dégrirmencı A, Ciçek C, Ak M, Korkmaz M, Gürüz Y, Uner A (2006) Behaviour of Toxoplasma gondii RH Ankara strain tachyzoites during continuous production in various cell lines. Parasitology 132: 315-319.
13. Jabari S, Keshavarz H, Salimi M, Morovati H, Mohebali M, Shojaee S (2018) In vitro culture of Toxoplasma gondii in HeLa, Vero, RBK and A549 cell lines. Infez Med 26: 145-147.
14. Winters S, Martin C, Murphy D, Shokar NK (2017) Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci 151: 1-32.
15. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.
16. Petrelli F, Barni S (2012) Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Med Oncol 29: 2586-2593.
17. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165: 5133-5142.
18. Döskaya M, Caner A, Ajzenberg D, Dégrirmencı A, Dardé ML, Can H, Erdoğan DD, Korkmaz M, Uner A, Güngör C, Altıntaş K, Gürüz Y (2013) Isolation of Toxoplasma gondii strains similar to Africa 1 genotype in Turkey. Parasitol Int 62: 471-474.
19. Döskaya M, Caner A, Can H, İz SG, Dégrirmencı A, Gürüz AY (2013) Cryopreservation of Toxoplasma gondii tachyzoites and tissue cysts. Türkiye Parazitol Derg 37: 44-46. [Article in Turkish].
20. Andreasson K, Tegerstedt K, Eriksson M, Curcio C, Cavallo F, Forni G, Dalianis T, Ramqvist T (2009) Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors. Int J Cancer 124: 150-6.
21. Pyo KH, Jung BK, Xin CF, Lee YW, Chai JY, Shin EH (2014) Prominent IL-12 production and tumor reduction in athymic nude mice after Toxoplasma gondii lysate antigen treatment. Korean J Parasitol 52: 605-612.
22. Rodrigues E, Macauley MS (2018) Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities. Cancers 10: 207.
23. Blumenschein TM, Friedrich N, Childs RA, Saouros S, Carpenter EP, Campanero-Rhodes MA, Simpson P, Chai W, Koutroukides T, Blackman MJ, Feizi T, Soldati-Favre D, Matthews S (2007) Atomic resolution insight into host cell recognition by Toxoplasma gondii. EMBO J 26: 2808-2820.

Corresponding author
Levent Yeniay. Present address: Ege University Faculty of Medicine, Department of General Surgery, Breast Cancer Unit, Bornova, İzmir, 35100, Turkey.
Tel: +90-232-3905075;
Fax: +90-232-3881347
E-mail: levent.yeniay@ege.edu.tr

Conflict of interests: No conflict of interests is declared.